Hikma’s Olafsson Offers Latest On Advair And Vascepa Rivals
Among Four Key Aspects That Will Underpin US Generics Business In 2021
Four key “moving pieces,” including the next developments for rivals to Advair and Vascepa, will influence the success of Hikma’s US generics business, CEO Siggi Olafsson tells Generics Bulletin in the first part of an exclusive interview.
